NexLife Semaglutide Review

NexLife prices competitively and, more notably, describes what it is selling accurately. Our research (September 1, 2026) found a compounded GLP-1 provider whose disclaimers are placed where they matter rather than buried, and whose treatment of BMI is more honest than most clinical websites manage.

Important: These Are Compounded Medications

NexLife states the position plainly:

"Compounded medications are not approved by the FDA and have not been reviewed for safety, effectiveness, or quality. Actual product packaging may vary from what is displayed. Charts are for illustrative purposes only."

That is the correct disclaimer, and the additional notes about packaging and illustrative charts address two things patients routinely misread on these sites. Where it matters most is alongside the efficacy claim. NexLife cites the Wegovy trial result and immediately separates it from what it sells:

"In clinical studies of the FDA-approved medication Wegovy®, participants lost an average of about 15% of their body weight... Only a licensed provider can determine whether an FDA-approved option is suitable. Compounded GLP-1 formulations are not FDA-approved."

Citing brand trial data next to a compounded product is the single most common misleading pattern in this category. NexLife cites it but attaches the correction, which is the right way to do it. The usual post-shortage caveat still applies. With the tirzepatide shortage resolved in October 2024 and semaglutide in early 2025, lawful 503A compounding now depends on a documented clinical reason for the individual patient rather than a shortage — worth raising with the prescriber.

BMI Is Described Accurately, Which Is Rare

NexLife publishes a BMI calculator, and then does something almost no competitor does — it undercuts its own tool:

"BMI does not directly measure body fat and may be less accurate for people with higher muscle mass, pregnant individuals, children, older adults, certain ethnic backgrounds, or those with underlying conditions. It should not be used as the sole indicator of health."

"The BMI calculator does not determine eligibility for weight-management treatment. A licensed healthcare provider must assess your full medical history to determine whether treatment may be appropriate."

Most operators use a BMI calculator as a conversion device: enter a number, receive a qualification. NexLife explicitly refuses that framing and routes the decision to a clinician assessing full medical history. Combined with "Get Evaluated by a Board Certified Provider," it describes a screen rather than a funnel.

Pricing

Compounded semaglutide starts at $139 per month and compounded tirzepatide at $169 per month, with GLP-1 treatments advertised elsewhere as low as $119 per month. All plans are stated to be FSA and HSA eligible, with free expedited delivery. Each price carries an asterisk, and what those asterisks resolve to — dose tiers, plan length, promotional conditions — is not fully set out. "Prices start from" and "as low as" both signal a floor rather than a typical cost, and no tier structure shows what a maintenance dose costs.

What Is Not Published

No named pharmacy and no 503A or 503B status. No BMI or clinical eligibility threshold — appropriately, given the company's own position that BMI should not determine eligibility, but that leaves the actual standard unstated. No lab requirements, titration protocol or monitoring schedule. No founding year, headquarters, named clinicians, refund terms or cancellation policy. And no reconciliation between the $119, $139 and $169 figures.